SREBF1 and metabolic dysfunction-associated steatotic liver disease: Previous studies have demonstrated that the activation of AMPK reduced the expression of triglyceride synthesis proteins, such as SREBP-1 and FAS, activated the expression of fatty acid β-oxidation proteins, such as CPT-1 and PPARα, and then inhibited the occurrence of NAFLD [26].